Researchclinical trialssepsis treatmentimmunomodulatorai sepsis detection
Griffith University Develops Drug Reversing Sepsis Damage
|
7.1
Researchers at Australia's Griffith University report Phase II human trial results in China for STC3141, a carbohydrate-based infusion that calms immune overreaction and reduced sepsis severity. The team plans Phase III effectiveness trials and hopes for market approval within a few years if results hold. Northeastern University also reported an AI model predicting septic shock with over 99% accuracy.
Scoring Rationale
Strong Phase II clinical results with broad global scope; limited by early-stage evidence and lack of peer-reviewed publication.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
Used by DS/ML engineers at top companies
250 free problems · No credit card
See all Health & Insurance problems
